FXR is used as a target for new drug therapies against metabolic dysregulation associated with obesity, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis as well as for the cholestatic liver disease primary biliary cholangitis4–7. Here, NR1H4 is linked to type 2 diabetes mellitus.